Background. Infections caused by carbapenem resistant Enterobacteriaceae (CRE) are associated with high mortality. Optimal treatment for CRE bacteremia remains unclear, including the role of combination therapy, carbapenem-containing regimens, or newer antimicrobials, such as ceftazidime-avibactam (CAZ-AVI). The objective of this study was to evaluate risk factors associated with mortality in patients with CRE bacteremia, with a focus on antimicrobial therapy.
Methods. This was a multicenter, retrospective cohort study of inpatients within Carolinas HealthCare System who had a positive blood culture with CRE (Klebsiella spp., Enterobacter spp., or Escherichia coli) between January 1, 2010 and September 30, 2016. CRE isolates were identified as pathogens with an ertapenem MIC ≥ 1 mcg/mL. The primary endpoint was death within 28 days after the first positive blood culture in patients with CRE bacteremia. Clinical variables, including the use of specific antimicrobials and combination therapy, were compared between 28-day survivors vs. non-survivors.
Results. A total of 73 patients were included with CRE bacteremia. The most common sources of infection identified were urine (42.5%) and intra-abdominal (38.4%). The overall 28-day mortality was 26%. Fifty-three (72.6%) patients received combination antibiotic therapy and 20 (27.4%) received monotherapy. Combination therapy with in vitro active agents (36.8% vs. 33.3%, P = 0.87) and the use of carbapenem-containing regimens (47.4% vs. 46.3%, P = 0.74) did not differ between those who died and survived, respectively. One patient treated with CAZ-AVI as monotherapy died, but only eight patients received this antibiotic. There was a trend towards higher use of tigecycline in the group that died compared with the group that survived (73.7% vs. 59.3%, P = 0.26).
Conclusion. There did not appear to be a difference in mortality at 28 days with the use of combination therapy or a carbapenem-containing regimen. While a statistically significant difference was not demonstrated, tigecycline-containing regimens may be associated with increased mortality in the treatment of CRE bacteremia. Larger prospective studies are necessary to further elucidate the role of combination therapy and newer agents, such as CAZ-AVI, in this patient population. Background. Ceftolozane-tazobactam (TOL-TAZ) is a novel cephalosporin/β-lactamase inhibitor combination with potent activity against Pseudomonas aeruginosa, including MDRPA. TOL-TAZ use for MDRPA infections has not been well-studied.
Methods. We conducted a retrospective study to describe outcomes of patients treated with TOL-TAZ for MDR Pseudomonas aeruginosa infections at 3 academic medical centers. Patients were age ≥ 18 years who had MDRPA isolated in culture and received TOL-TAZ for at least 24 hours. The primary outcomes were 30-day and in-hospital mortality. Secondary outcomes were microbiological cure and clinical success. Microbiological cure was defined as negative culture at end of therapy; cure was presumed when clinical success occurred without follow-up cultures. Clinical success was defined as resolution of all signs and symptoms of infection. TOL-TAZ susceptibility results were collected when available.
Results. Conclusion. In this severely ill population with MDRPA infections, 79.4% and 76.5% of patients were alive at 30-days and at the end of their stay, respectively. Some patients had positive cultures despite clinical resolution. TOL-TAZ is a potential option for patients with MDRPA infections.
Background. Salmonella is a leading cause of foodborne enterocolitis worldwide. Nontyphoidal Salmonella (NTS) infections that are Multi-Drug-resistant (MDR) (non-susceptible to ≥1 agent in ≥3 antimicrobial categories) may result in more severe health outcomes, although these effects have not been systematically examined. We conducted a systematic review and meta-analysis to examine impacts of MDR NTS on disease outcomes in high-income settings.
Methods. We systematically reviewed the literature from scientific databases, including PubMed, Scopus and grey literature sources, using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We included case-control studies, cohorts, outbreaks, and theses, imposing no language restriction. We included only publications from 1 January 1990 through 15 September 2016 from high-income countries as classified by the World Bank, and extracted data on duration of illness, hospitalization, morbidity and mortality of MDR and susceptible NTS infections.
Results. After we removed duplicates, the initial search revealed 4 258 articles. After further screening, we identified 16 eligible studies for the systematic review, but due to inconsistency in the compared groups, only 9 of these were included in the meta-analysis. NTS serotypes differed among the reported studies but serotypes Typhimurium, Enteritidis, Newport, and Heidelberg were the most often reported MDR pathogens. Salmonella infections that were MDR were associated with excess bloodstream infections (OR 1·73; 95% CI 1·32-2·27), excess hospitalizations (OR 2·51; 95% CI 1·38-4·58), and higher mortality (OR 3·54; 95% CI 1·10-11·40).
Conclusion. The results of this meta-analysis suggest that MDR NTS infections have more serious health outcomes compared with susceptible isolates. With the emergence of MDR Salmonella strains in high-income countries, it is crucial to restrict the use of antimicrobials in animals and humans, and intervene to prevent foodborne infections.
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Background.
Vancomycin is historically correlated with renal toxicity, especially in conjunction with other nephrotoxins. Recent reports have identified nephrotoxicity associated with vancomycin in conjunction with β-lactam antibiotic therapy, reporting increased rates of acute kidney injury (AKI) with vancomycin/piperacillin-tazobactam (VPT) therapy as compared with vancomycin monotherapy. Similarly, increased rates of AKI have been reported with VPT as compared with vancomycin/cefepime. Little data exists comparing VPT to the combination of vancomycin/meropenem (VM). The purpose of this study was to compare the incidence of nephrotoxicity between these two antibiotic combinations.
Methods. A single-center cohort study was performed at a large tertiary care community hospital utilizing retrospective review of electronic medical records. Adult in-patients treated from June to October of 2015 were included. Evaluable patients received at least 48 hours of either VPT or VM combination therapy and were followed for up to 10 days of combination therapy. Data collection included patient demographics, AKI risk factors, days of antibiotic therapy, and serum creatinine. The primary endpoint was incidence of AKI as defined by the Kidney Disease Improving Global Outcomes (KDIGO) criteria. Secondary endpoints included time to AKI and incidence of new dialysis treatment.
Results. Of 564 patients screened, a total of 202 patients met inclusion criteria, with 101 patients in each combination therapy group. Baseline serum creatinine and estimated creatinine clearance were not different between groups. The incidence of AKI was higher in the VPT group as compared with the VM group (17.82% vs. 4.95%, respectively, P = 0.004). Time to AKI onset was longer in the VPT group compared with the VM group (3.2 days vs. 1.4 days, P = 0.045). Patients in the VM group had a higher incidence of ICU admissions (56.4% vs. 40.6%, P = 0.024) and mean arterial pressure (MAP) less than 65mmHg (60.4% vs. 44.6%, P = 0.029). No patients in either group required new dialysis therapy.
Conclusion. Despite a greater incidence of AKI risk factors in the VM group, VPT therapy was associated with an increased risk of AKI as compared with VM therapy. Prospective studies are needed to further evaluate this finding.
Disclosures. All authors: No reported disclosures. Results. There were a total of 77 AML patients with enterococcal BSI. Forty-two (54.5%) were caused by VRE. E. faecalis and E. faecium accounted for 28.5% and 62.3% of BSI respectively. The E. faecalis isolates were more likely to be VSE (83% vs. 8.3 %, P < 0.001) and E. fecium isolates to be VRE (71% vs. 29%, P < 0.001). Duration of neutropenia was significantly longer (27.3 vs. 20.7 days, P < 0.005) among AML patients with VRE BSI. Recent Vancomycin use and VRE colonization were significantly associated
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